BioRestorative Therapies Stock Price, News & Analysis (OTCMKTS:BRTX) $1.81 +0.05 (+2.84%) (As of 12/6/2023 ET) Add Compare Share Share Today's Range$1.70▼$1.8950-Day Range$1.58▼$2.2852-Week Range$1.41▼$7.13Volume16,542 shsAverage Volume191,954 shsMarket Capitalization$8.52 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC Filings About BioRestorative Therapies Stock (OTCMKTS:BRTX)BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Read More BRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRTX Stock News HeadlinesNovember 9, 2023 | cnet.comBest Light Therapy Lamps for 2023October 9, 2023 | finance.yahoo.comBioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York CityDecember 7, 2023 | Edge On The Street (Ad)Henry Ford Would NEVER Have Seen This ComingIn 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.September 18, 2023 | seekingalpha.comBioRestorative Therapies' 10% shareholder Broadrick Dale increases holdingSeptember 18, 2023 | finance.yahoo.comRoth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”September 12, 2023 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Enters into Supply Agreement with Evolutionary BiologicsSeptember 12, 2023 | stockhouse.comBioRestorative Therapies Enters into Supply Agreement with Evolutionary BiologicsSeptember 8, 2023 | finance.yahoo.comBioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc DiseaseDecember 7, 2023 | Edge On The Street (Ad)Henry Ford Would NEVER Have Seen This ComingIn 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.August 30, 2023 | msn.com$BRTX Is Looking To Treat Chronic Pain Without The Need For Class-A DrugsAugust 29, 2023 | benzinga.comAs America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A DrugsAugust 15, 2023 | msn.comRoth MKM Reiterates BioRestorative Therapies (BRTX) Buy RecommendationAugust 8, 2023 | finance.yahoo.comMirati (MRTX) Reports Q2 Loss, Misses Revenue EstimatesJuly 27, 2023 | msn.com$BRTX: Insights From A Specialist On Stem Cell-Based Therapies And The Need For Spinal Care ReformJuly 27, 2023 | finance.yahoo.comInsider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX)July 21, 2023 | finanznachrichten.deBioRestorative Therapies, Inc.: BioRestorative Therapies Receives Landmark License From New York StateJuly 21, 2023 | finance.yahoo.comBioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York StateJuly 18, 2023 | msn.com$BRTX's Drug Candidate BRTX-100 Excels In Safety Test, Advances To Phase 2 And Expands PipelineJuly 11, 2023 | msn.comWhy BioRestorative Therapies (BRTX) Stock Is Getting HammeredJuly 11, 2023 | finance.yahoo.comBioRestorative Therapies Announces $2.1 Million Registered Direct OfferingJuly 7, 2023 | finance.yahoo.comBioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline OpportunitiesJune 27, 2023 | benzinga.comEXCLUSIVE: Data Monitoring Committee Allows BioRestorative's Chronic Lumbar Disc Disease To Continue UnchangedJune 27, 2023 | finance.yahoo.comBioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any ChangesJune 27, 2023 | finance.yahoo.comEXCLUSIVE: Data Monitoring Committee Allows BioRestorative's Chronic Lumbar Disc Disease Study To Continue UnchangedJune 26, 2023 | finance.yahoo.comBioResorative CEO is Featured in An Interview With SmallCaps DailyJune 17, 2023 | finance.yahoo.comIs BioRestorative Therapies (NASDAQ:BRTX) In A Good Position To Invest In Growth?June 16, 2023 | finance.yahoo.comBioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ETSee More Headlines Receive BRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today12/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BRTX CUSIPN/A CIK1505497 Webwww.biorestorative.com Phone(631) 760-8100FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+729.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,500,000.00 Net Margins-13,728.83% Pretax Margin-13,728.83% Return on Equity-120.47% Return on Assets-114.48% Debt Debt-to-Equity RatioN/A Current Ratio14.81 Quick Ratio14.81 Sales & Book Value Annual Sales$130,200.00 Price / Sales65.41 Cash FlowN/A Price / Cash FlowN/A Book Value$2.65 per share Price / Book0.68Miscellaneous Outstanding Shares4,707,000Free Float3,660,000Market Cap$8.52 million OptionableNot Optionable Beta58.92 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Lance Alstodt (Age 52)Chairman of the Board, President & CEO Comp: $400kMr. Robert Eugene Kristal (Age 55)Chief Financial Officer Comp: $175kMr. Francisco J. Silva (Age 48)Chief Scientist, VP of Research & Development, Secretary and Director Comp: $375kMr. Robert Paccasassi (Age 54)Vice President of Quality Assurance & Regulatory Compliance Comp: $233.95kDr. Wayne J. Olan M.D.Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory BoardKey CompetitorsImunonNASDAQ:IMNNOragenicsNYSEAMERICAN:OGENPreveCeutical MedicalOTCMKTS:PRVCFTherapix BiosciencesOTCMKTS:TRPXYBright Minds BiosciencesNASDAQ:DRUGView All CompetitorsInsidersDale BroadrickBought 1,000 shares on 7/27/2023Total: $2,800.00 ($2.80/share)Lance AlstodtBought 4,200 shares on 7/25/2023Total: $10,248.00 ($2.44/share)Francisco SilvaBought 747 shares on 3/31/2023Total: $2,659.32 ($3.56/share)Dale BroadrickBought 6,000 shares on 2/22/2023Total: $17,160.00 ($2.86/share)Lance AlstodtBought 400 shares on 2/1/2023Total: $1,240.00 ($3.10/share)View All Insider Transactions BRTX Stock Analysis - Frequently Asked Questions Should I buy or sell BioRestorative Therapies stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BRTX shares. View BRTX analyst ratings or view top-rated stocks. What is BioRestorative Therapies' stock price target for 2024? 1 Wall Street research analysts have issued 12-month price objectives for BioRestorative Therapies' stock. Their BRTX share price targets range from $15.00 to $15.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 729.0% from the stock's current price. View analysts price targets for BRTX or view top-rated stocks among Wall Street analysts. How have BRTX shares performed in 2023? BioRestorative Therapies' stock was trading at $2.75 at the start of the year. Since then, BRTX shares have decreased by 34.2% and is now trading at $1.8094. View the best growth stocks for 2023 here. How were BioRestorative Therapies' earnings last quarter? BioRestorative Therapies, Inc. (OTCMKTS:BRTX) issued its quarterly earnings results on Monday, November, 13th. The company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.04. The firm had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 120.47% and a negative net margin of 13,728.83%. When did BioRestorative Therapies' stock split? BioRestorative Therapies shares reverse split before market open on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. What other stocks do shareholders of BioRestorative Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX) and OPKO Health (OPK). How do I buy shares of BioRestorative Therapies? Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (OTCMKTS:BRTX) was last updated on 12/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.